Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
McKesson
Moodys
Baxter
AstraZeneca

Last Updated: October 1, 2022

CLINICAL TRIALS PROFILE FOR ADCETRIS


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for ADCETRIS

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00848926 ↗ A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma Completed Millennium Pharmaceuticals, Inc. Phase 2 2009-02-01 This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory Hodgkin lymphoma.
NCT00848926 ↗ A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma Completed Seagen Inc. Phase 2 2009-02-01 This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory Hodgkin lymphoma.
NCT00848926 ↗ A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma Completed Seattle Genetics, Inc. Phase 2 2009-02-01 This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory Hodgkin lymphoma.
NCT00866047 ↗ A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma Completed Millennium Pharmaceuticals, Inc. Phase 2 2009-03-01 This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory ALCL.
NCT00866047 ↗ A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma Completed Seagen Inc. Phase 2 2009-03-01 This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory ALCL.
NCT00866047 ↗ A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma Completed Seattle Genetics, Inc. Phase 2 2009-03-01 This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory ALCL.
NCT00947856 ↗ A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study Completed Millennium Pharmaceuticals, Inc. Phase 2 2009-07-01 This is a multicenter, open-label study to evaluate the safety and efficacy of treatment with brentuximab vedotin (SGN-35) in patients who have previously participated in an brentuximab vedotin study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ADCETRIS

Condition Name

Condition Name for ADCETRIS
Intervention Trials
Hodgkin Lymphoma 14
Refractory Hodgkin Lymphoma 8
Recurrent Hodgkin Lymphoma 8
Classic Hodgkin Lymphoma 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ADCETRIS
Intervention Trials
Lymphoma 70
Hodgkin Disease 48
Lymphoma, Non-Hodgkin 19
Lymphoma, Large-Cell, Anaplastic 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ADCETRIS

Trials by Country

Trials by Country for ADCETRIS
Location Trials
United States 527
Canada 30
Spain 18
United Kingdom 16
France 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ADCETRIS
Location Trials
California 32
Texas 29
New York 26
Washington 22
Illinois 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ADCETRIS

Clinical Trial Phase

Clinical Trial Phase for ADCETRIS
Clinical Trial Phase Trials
Phase 4 2
Phase 3 4
Phase 2 50
[disabled in preview] 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ADCETRIS
Clinical Trial Phase Trials
Recruiting 23
Completed 23
Active, not recruiting 18
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ADCETRIS

Sponsor Name

Sponsor Name for ADCETRIS
Sponsor Trials
Seagen Inc. 30
National Cancer Institute (NCI) 27
Seattle Genetics, Inc. 24
[disabled in preview] 32
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ADCETRIS
Sponsor Trials
Industry 80
Other 79
NIH 27
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Medtronic
Baxter
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.